AIM ImmunoTech Inc.

AIM

US00901B3033

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2026-05-15 pm EDT			5-day change	1st Jan Change
0.2530 ^USD	-1.94%		-54.82%	-77.59%

May. 07	Aim ImmunoTech announces 50% objective response rate (ORR) in UPMC recurrent ovarian cancer Phase 2 clinical trial, suggesting breakthrough combination potential	RE
May. 07	Aim Immunotech Inc Announces 50% Objective Response Rate in Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial	CI

AIM ImmunoTech Starts Late-Stage Trial of Ampligen in Pancreatic Cancer

Published on 04/16/2026 at 12:07 pm EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about AIM ImmunoTech Inc.

May. 07	Aim ImmunoTech announces 50% objective response rate (ORR) in UPMC recurrent ovarian cancer Phase 2 clinical trial, suggesting breakthrough combination potential	RE
May. 07	Aim Immunotech Inc Announces 50% Objective Response Rate in Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial	CI
Apr. 16	AIM ImmunoTech Starts Late-Stage Trial of Ampligen in Pancreatic Cancer	MT
Apr. 16	AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen in Pancreatic Cancer	CI
Apr. 13	Aim ImmunoTech provides routine update on annual filings	RE
Mar. 27	AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 26	AIM ImmunoTech Inc. Auditor Raises 'Going Concern' Doubt	CI
Mar. 18	AIM ImmunoTech Inc Announces Final Approval Of Novel Cancer Therapy Patent In Japan Combining Ampligen With Checkpoint Inhibitors	CI
Mar. 18	AIM ImmunoTech announces final approval of novel cancer therapy patent in Japan combining Ampligen with checkpoint inhibitors	RE
Mar. 04	Aim ImmunoTech announces expiration and preliminary results of its rights offering for aggregate gross proceeds of $1.8 million	RE
Mar. 02	AIM ImmunoTech signs agreement for planning of a proposed Phase 3 clinical trial of Ampligen in the treatment of late-stage pancreatic cancer	RE
Mar. 02	AIM ImmunoTech Signs Agreement for Planning of A Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer	CI
Feb. 25	Aim Immunotech announces extension of subscription period	RE
Feb. 23	Aim Immunotech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and Astrazeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer	CI
Feb. 11	AIM ImmunoTech announces commencement of rights offering	RE

AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Companyâ€™s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Employees

Sector

Biotechnology & Medical Research

More about the company